We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEvotec SE ADR

Evotec SE ADR

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
1.655 USD -0.04 ( 2.07%)
Last update at 2026-11-12T15:17:00Z
VOLUME
20375
Market Cap
579.28M

Momentum Score

…

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.64
Low
1.66
High
52 Week Price Range
1.60
Low
4.27
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Evotec SE ADR provides drug discovery and early development services to pharmaceutical and biotechnology clients, offering integrated discovery platforms, research services and early-stage development capabilities. Long-term growth may be supported by secular demand for outsourced R&D, expansion of platform technologies and deal-driven milestone revenues. Investors may find exposure attractive for recurring service cash flows combined with upside from high-value collaborations.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.69
Dividend Yield
-
Revenue TTM
717.28M
Revenue Per Share
2.02
Gross Profit TTM
60.71M
Debt / Equity
0.55
ROE
-26.08%
Net Debt
29.16M
ROCE
-9.60%
Diluted EPS TTM
-0.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -123.31M -193.98M -103.84M -153.96M 236.98M
Minority interest - - - 0.00M 0.00M
Net income -99.43M -196.08M -83.91M -175.66M 215.51M
Selling general administrative 175.97M 170.72M 152.74M 142.70M 96.02M
Selling and marketing expenses - 17.48M 16.87M 13.49M 9.42M
Gross profit 62.66M 114.88M 175.05M 174.06M 151.54M
Reconciled depreciation 99.48M 101.62M 92.98M 81.66M 70.40M
Ebit -135.31M -182.28M -7.33M 12.49M 27.32M
Ebitda -39.76M -80.66M -7.16M 94.15M 94.93M
Depreciation and amortization 95.55M 101.62M 0.17M 81.66M 67.61M
Operating income -135.31M -142.52M -107.09M 12.49M 27.32M
Other operating expenses 892.57M 939.49M 888.51M 730.60M 576.36M
Interest expense 13.87M 11.70M 11.74M 13.15M 9.25M
Tax provision 16.75M 2.10M 3.32M 21.70M 21.47M
Interest income 4.42M 2.44M 9.26M 8.34M 2.27M
Net interest income -10.02M -9.26M -2.48M -4.81M -6.98M
Income tax expense -23.88M 2.10M -40.68M 21.70M 21.47M
Total revenue 757.26M 796.97M 781.43M 751.45M 618.03M
Total operating expenses 197.97M 257.40M 282.14M 153.22M 109.86M
Cost of revenue 694.60M 682.09M 606.38M 577.38M 466.49M
Total other income expense net 12.00M -51.45M 3.25M -166.45M 209.66M
Net income from continuing ops -103.52M -196.08M -83.91M -175.66M 215.51M
Net income applicable to common shares - - - - 215.51M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1778.00M 1912.50M 2299.05M 2257.25M 2235.16M
Intangible assets 31.56M 26.44M 15.45M 23.82M 30.85M
Other current assets 43.71M 35.66M 64.11M 40.18M 20.68M
Total liab 964.64M 959.98M 1179.14M 1070.06M 857.48M
Total stockholder equity 813.36M 952.52M 1119.91M 1187.18M 1377.68M
Other current liab 91.52M 84.21M 73.31M 87.38M 74.53M
Common stock 177.70M 177.55M 177.19M 176.95M 176.61M
Capital stock 177.78M 177.55M 177.19M 176.95M 176.61M
Retained earnings -775.56M -672.37M -476.29M -392.38M -216.42M
Other liab - - - - 70.65M
Good will 272.25M 282.85M 275.63M 274.82M 257.57M
Other assets - - 0.00M - 79.34M
Cash 418.34M 306.39M 510.91M 415.15M 699.33M
Total current liabilities 367.92M 344.58M 464.57M 337.71M 324.52M
Current deferred revenue 108.02M 109.81M 107.86M 136.67M 126.78M
Net debt 29.16M 137.15M 115.29M 91.52M -186.41M
Short term debt 103.64M 50.80M 149.09M 16.38M 50.61M
Short long term debt 104.72M 50.80M - 1.56M 36.14M
Short long term debt total 447.50M 443.54M 626.20M 506.67M 512.92M
Other stockholder equity 1456.30M 1454.69M 1449.65M 1440.01M 1430.14M
Property plant equipment - - - - 484.60M
Total current assets 762.62M 681.96M 903.16M 1073.67M 1100.94M
Long term investments 52.63M 42.15M 142.09M 150.33M 287.01M
Net tangible assets - - - - 1089.27M
Short term investments 57.85M 90.41M 93.20M 314.83M 159.17M
Net receivables 213.42M 218.38M 204.06M 256.74M 176.75M
Long term debt 344.01M 392.74M - 328.30M 326.34M
Inventory 29.30M 31.12M 30.89M 29.82M 25.79M
Accounts payable 64.74M 85.79M 134.32M 97.28M 72.60M
Accumulated other comprehensive income -45.09M -7.35M -30.64M -37.40M -12.64M
Non currrent assets other 36.84M 37.82M 95.23M 74.08M 56.84M
Non current assets total 1015.38M 1230.54M 1395.89M 1183.58M 1134.22M
Capital lease obligations 22.18M - - 176.82M 150.44M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 31.97M -71.19M -13.29M -415.82M -117.13M
Change to liabilities - - - 0.00M 94.42M
Total cashflows from investing activities 159.86M -71.19M - - -243.85M
Net borrowings -29.42M -152.07M - - -5.89M
Total cash from financing activities -30.93M -161.42M 84.82M -52.41M 398.43M
Change to operating activities - - - - -55.87M
Net income -99.43M -196.08M -83.91M -175.66M 215.51M
Change in cash 148.32M -204.52M 95.75M -284.17M 276.75M
Begin period cash flow 270.02M 510.91M 415.15M 699.33M 422.58M
End period cash flow 418.34M 306.39M 510.91M 415.15M 699.33M
Total cash from operating activities -9.06M 18.22M 33.95M 203.11M 122.24M
Issuance of capital stock - 0.00M 0.22M 0.35M 403.13M
Depreciation 95.55M 101.62M 99.92M 81.66M 67.61M
Other cashflows from investing activities - -2.78M - - -
Dividends paid 0.00M 0.00M 0.00M - -
Change to inventory -9.18M -2.69M - -4.41M -11.65M
Change to account receivables -27.60M -40.74M - -38.43M -48.03M
Sale purchase of stock -1.55M 0.00M - - -
Other cashflows from financing activities -22.71M -9.35M -12.63M 0.34M 31.99M
Change to netincome - - - - -158.60M
Capital expenditures 69.68M 132.24M 216.00M 181.35M 118.94M
Change in working capital -58.40M -68.21M -9.94M 119.26M -2.28M
Stock based compensation 3.78M 5.04M 9.63M 9.92M 7.80M
Other non cash items 39.11M 173.75M 232.33M 160.20M -171.47M
Free cash flow -78.74M -114.02M -182.05M 21.75M 3.29M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EVO
Evotec SE ADR		 -0.04
2.07%		 1.66 - 20.62 0.81 0.77 0.70 34.36
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Evotec SE ADR

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Essener Bogen 7, Hamburg, Germany, 22419

49 40 560 81 0

https://www.evotec.com

4461

Name Title Year Born
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D. Chairman of Management Board & CEO 1968
Mr. Enno Spillner CFO & Member of Management Board 1970
Dr. Cord Dohrmann Ph.D. Chief Scientific Officer & Member of Management Board 1964
Dr. Craig Johnstone COO & Member of Management Board 1970
Dr. Matthias Evers Chief Bus. Officer & Member of Management Board 1973
Ms. Anja Bosler Principal Accounting Officer and Sr. VP of Group Accounting NA
Mr. Volker Braun Sr. VP and Global Head of Investor Relations & ESG NA
Dr. Christian Dargel EVP Global Head of Legal & Compliance NA
Gabriele Hansen Sr. VP & Head of Global Corp. Communications & Marketing NA
Ms. Monika Conradt Global Head of HR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…